Multiyear partnership will leverage Valo’s Opal Computational Platform to accelerate drug discovery and development
WILMINGTON, Mass. & BOSTON–(BUSINESS WIRE)–$CRL #LIFEatCRL–Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, LLC (“Valo”), the technology company using human-centric data and computation powered by artificial intelligence (AI) to transform the drug discovery and development process, today announced the formation of a multiyear strategic partnership. This agreement will combine Valo’s Opal Computational Platform with Charles River’s drug discovery and development capabilities to offer a new transformative, AI-enabled drug discovery and development platform.
Recognizing the challenges of preclinical drug discovery, from high costs, time, and attrition rates, Valo and Charles River have joined forces to create enhanced drug discovery solutions that aim to transform the entire preclinical drug discovery process. Valo and Charles River intend to create and deliver offerings that produce preclinical assets with key performance characteristics optimized for client preferences.
The partnership’s combined offerings will utilize Valo’s Opal Platform for small molecule development, which leverages a “closed-loop” in silico-experimental platform that rapidly iterates using program data to identify novel compounds, and leverages Charles River’s capabilities in all aspects of discovery optimization, including medicinal chemistry, ADME, biology, pharmacology, and ultimately safety testing and IND submission.
The combination of Valo’s scientific innovation and deep technological expertise with Charles River’s end-to-end portfolio and industry-leading scientific bench has the potential to significantly accelerate a client’s discovery and development efforts by integrating data and compute to streamline and de-risk experimental science, enabling a faster and more effective process from de novo molecule design through lead optimization.
The combined offering will be launched in the first half of 2022 and will be available exclusively from Charles River.
Approved Quotes
- “Our collaboration with Valo is another step we’re taking toward accelerating drug discovery and development. By leveraging disruptive, AI-powered tools like Opal, we can support our clients in more quickly progressing their discoveries to the clinic.” – Birgit Girshick, Corporate Executive Vice President & Chief Operating Officer, Charles River
- “We are thrilled to partner with Charles River to build these enterprise solutions and deliver them to clients. We see this as an important opportunity to help drive a change in the industry and make a significant impact to deliver better drugs to patients faster – building off each of Valo’s and Charles River’s unique capabilities.” –David Berry, MD, PhD, Founder and CEO of Valo Health
About Valo Health
Valo Health, LLC (“Valo”) is a technology company built to transform the drug discovery and development process using human-centric data and artificial intelligence (“AI”) computation. As a digitally native company, Valo aims to full integrate human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate. The company’s Opal Computational Platform™ consists of an integrated set of capabilities designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs across cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, San Francisco, CA, Princeton, NJ, and in Branford, CT. To learn more, visit www.valohealth.com.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Contacts
Charles River Investor Contact:
Todd Spencer
Corporate Vice President, Investor Relations
+1- 781-222-6455
todd.spencer@crl.com
Charles River Media Contact:
Amy Cianciaruso
Corporate Vice President & Chief Communications Officer
+1-781-222-6168
amy.cianciaruso@crl.com
Valo Health Investor Contact:
Graeme Bell
Chief Financial Officer
+1-267-326-2129
Gbell@valohealth.com
Valo Health Media Contact:
Jennifer Hanley
Vice President & Head of Corporate Communications
Jhanley@valohealth.com